Huang Dennis Karl 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Huang Dennis Karl
See Remarks
Transactions
- Award
Common Stock
2025-03-01+14,494→ 97,496 total - Award
Common Stock
2025-03-01+18,443→ 115,939 total - Award
Stock Option (Right to Buy)
2025-03-01+26,074→ 26,074 totalExercise: $42.92Exp: 2035-03-01→ Common Stock (26,074 underlying) - Tax Payment
Common Stock
2025-03-03$42.92/sh−1,348$57,856→ 114,591 total
Footnotes (5)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
- [F3]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.